Non-IgE mediated mechanisms of food allergy

Antonella Cianferoni, MD PhD FAAAAI


## DIVISION OF ALLERGY AND IMMUNOLOGY THE CHILDREN'S HOSPITAL OF PHILADELPHIA UNIV. OF PENNSYLVANIA, PHILADELPHIA, PA, USA







- PI in DBV SMILEE trial (protect time to conduct research)
- FARE Co-director of the FARE CHOP Center (protect time to conduct research)
- Sanofi consultants
- AAAAI-BCI secretary -volunteer
- EAACI-EoE IG-Board-volunteer

# **Adverse Reactions to Foods**






## Food Antigen Type 1 access to the mucosal immune system



Chehade M et al JACI 2005, Heyman M et al Proc Nutr Soc 2001



## **Epithelial barrier**


Epithelial cells are held together and communicate through junctions formed by transmembrane proteins

-**tight junction** (claudins and tight junctionassociated MARVEL proteins (TAMPs));

-adherens junction (E-cadherin)


-**desmosome** (desmogelin and desmocollin) They are connected to the actin cytoskeleton via cytosolic proteins (ZO1, catenins and desmoplakin).

Tight and adherens junctions interact with the actin cytoskeleton, and desmosomes connect to intermediate filaments.








# Oral tolerance: role of T cells




## **Oral tolerance: role of T cells activation**








# **Oral tolerance: Treg in the gut**



Bacchetta R et al JACI 2007 Chehade M et al JACI 2005


# **Oral tolerance: role of T cells**




### **Chehade M et al JACI 2005**

## **Non-IgE mediated food allergy**

- Celiac DELAYED REACTION-CHRONIC INFLAMMATION Th1 inflammation
- Eosinophlic Esophagitis (DELAYED REACTION-CHRONIC INFLAMMATION) Th2 inflammation
- FPIES (DELAYED REACTION-ACUTE INFLAMMATION)





## **Celiac disease (CD) : Definition**

- Celiac disease is a chronic, small-intestinal immune mediated enteropathy initiated by exposure to dietary gluten in genetically predisposed individuals and characterized by specific autoantibodies against tissue transglutaminase 2 (antitTG2), endomysium, and/or deamidated gliadin peptide
- The genotype *HLA-DQ2* or *HLA-DQ8*, which is required for the development of celiac disease. Although up to 40% of the population carries, only 2%to 3% of *HLA-DQ2* or *HLA-DQ8* carriers subsequently develop celiac disease
- CD can develop at any age and can affect almost any race.
- Prevalence is 1% with regional differences (0-5.6%)
- Some patients such as patients with IgA deficiency, Autoimmune diseases of Thyroid and or Liver, Down Syndrome, Turner Syndrme, IgA nephropathy, Juvenile arthritis, William Syndrome are at higher risk (1.5- 13.5%)

Di Sabatino A, 2009 Leonard MM et al, 2017

## **Celiac disease (CD) : Manifestation**

## Intestinal Manifestations (more common in children)

- Children < 3 years : diarrhea, loss of appetite, abdominal distention, and poor growth.
- Children 3 > years or adults : diarrhea, bloating, constipation, abdominal pain, or weight loss.

## Extraintestinal Manifestations (due to inflammation, nutrient deficiencies)

- Poor growth, short stature, or delayed puberty (pre puberty)
- Dental enamel defects are (children < 7 years).
- Iron-deficiency anemia (in 32% of adults and 9% of children)
- An increased risk of miscarriage (woman)
- Skin manifestation: dermatitis herpetiformis, urticaria, psoriasis, and dry skin Neurological manifestation or psychiatric manifestationsor both (up to 22% of patients with CD)
- Peripheral neuropathy is frequent, compared with healthy controls (nutritional deficit or inflammation)

**Refractory celiac disease** is defined as persistent or recurrent malabsorptive symptoms and villous atrophy despite strict adherence to a gluten-free diet for at least 6 -12 months. Uncommon and severe complications such as ulcerative jejunitis and enteropathyassociated T-cell lymphoma

## Silent coeliac disease

- Patients who do not complain of any symptoms and do not seek medical advice
- Most of these patients are relatives of patients with known coeliac disease or members of the general population found to be positive at the search for antiendomysial antibodies or hTTG antibodies

## Minor coeliac disease

• Patients complaining of trivial, transient, or apparently unrelated symptoms (dyspepsia, abdominal discomfort and bloating, mild or occasional altered bowels habit without malabsorption mimicking irritable bowel syndrome, unexplained anaemia, isolated fatigue, cryptic hypertransaminasaemia, infertility, peripheral and central neurologic disorders, osteoporosis, short stature, dental enamel defects, dermatitis herpetiformis), or of isolated symptoms of autoimmune diseases often reported in association with coeliac disease

• Most of these patients are biopsied after positive search of antiendomysial antibodies or hTTG antibodies

## Major coeliac disease

• Patients complaining of frank malabsorption symptoms (diarrhoea which is often nocturnal and with incontinence, steatorrhoea suggested by loose discoloured, greasy, and frothy stools that are diffi cult to fl ush away, weight loss and other features of malnutrition, cramps, tetany, and peripheral oedema due to electrolyte and albumin depletion); symptoms of other autoimmune diseases may be associated

• Most of these patients are biopsied only on the basis of symptoms

### Di Sabatino A, 2009

## **Celiac disease (CD) : Diagnosis**

**Serology:** anti-tissue transglutaminase (tTG-IgA), anti-endomysial (EMA-IgA), anti-Deamidated gliadin peptides (DGP-IgG)


Table 3. Range of Sensitivity and Specificity and Use of Current Serologic Tests for Celiac Disease<sup>a</sup>

Serologic	%		
Study	Sensitivity	Specificity	Application in Clinical Practice
lgA tTG	73.9-100	77.8-100	First-line testing to screen for celiac disease <sup>b</sup>
IgG DGP	80.1-96.9	86.0-96.9	First-line testing for celiac disease in patients with IgA deficiency
IgA EMA	82.6-100	94.7-100	Second-line confirmatory test to screen for celiac disease
lgG tTG	12.6-99.3	86.3-100	Not recommended for routine use because of poor sensitivity compared with IgG DGP
IgA DGP	80.7-95.1	86.3-93.1	Not recommended for routine use because of poor sensitivity and specificity compared with IgA tTG and IgA EMA

## **Biopsy (Duodenum)**

- increased number of intraepithelial lymphocytes (>25 per 100 enterocytes)
- elongation of the crypts
- partial to total villous atrophy

### **Celiac Disease: Th1 mediated autoimmune**



## **Celiac Disease: Gluten**

Bread wheat (Triticum aestivum) is a globally important food crop

Accounts for 20% of the calories consumed by humans.

It is an important source of protein, vitamins, and minerals.

Storage proteins in wheat are collectively referred to as gluten, give viscosity to dough

Gluten is actually an aggregate formed from two major types of protein:


Gliadin (soluble in 70-90% acqueos alcohol) – prolamin-flow of dough

Glutenin (insoluble in alcohol)-glutelins-elasticity

[Plant proteins are categorized in: albumins, globulins, prolamins, and glutelins].

Glutenin is composed of macropolymers, huge polymers of high- and low-molecular weight subunits crosslinked with disulfide bonds.

These macropolymers intermingle randomly with individual particles of gliadins to form the aggregate, which is held together with non-covalent interactions



### **Celiac Disease: Gluten genes**

Gluten proteins show extensive polymorphism.

The number of genes encoding gluten proteins increased by duplication and translocation events.

The amino acid sequences of these additional genes have altered due to substitution, deletion, and insertion events during their evolution, apparently in the absence of strong selection pressure.


These changes have resulted in complex mixtures of homologous proteins that vary widely in molecular mass and charge.

This variation has made the isolation and study of these proteins difficult.

Wheat cells have genomes A, B, and D.

γ- and ω-gliadins =Gli-A1, Gli-BI, and Gli-DI, located on the short arms of the group 1 chromosomes. γ-gliadins 15–40 copies of genes and ω-gliadins 15–18 copies The α-and β-gliadins= Gli-A2, Gli-B2, and Gli-D2 on the short arms of the group 2 chromosomes. 25 to 150 copies of the genes (similar so now only α-gliadin)


Gliadins are soluble in pure water when they are at concentrations of less than 10% by weight (wt%). At these concentrations, they yield a transparent solution. When they are in solutions of greater than approximately 15 wt%, gliadins form gel-like hydrated solids. These will not flow even if the container is inverted at 40 wt% or more



Olygiutamine-1       Polygiutamine-2            ar-gliadins           sig N         R         Cr         Cr         Cr					
	α-gliadin (30-34KD)	γ-gliadin (26-36kD)	ω-gliadin		
SIG(signal peptide)	20 AA	19 AA	19 AA		
N(N-terminal region)	5 residues	12 residues	11 residues		
R (repetitive domain)	110-130 residues P(F/Y)PQ3–5.	80-160 residues PFPQQ0– 1(PQQ)1–2	238 residues PFPQ1–2PQ1–2		
C1 (cysteine rich)	4 cysteine	6 cysteine	No cysteines		
CII (glutamine rich)	Glutamine residues	Glutamine res			
CIII	35-39 residues+2 cysteines	41-43 residues+2 cysteines			
Black boxes	2 polyglutamine peptides				

Urade R, 2018


## Celiac Disease: Why you develop it?



Genetic factors


- basis of familial aggregation
- a concordance rate of about 85% between monozygotic twins
- COELIAC1 6p21-HLA-DQ (strong but mono-zygotes twins stronger than HLA identical)
  - DQ2 (alleles DQA1\*05/DQB1\*02)
  - DQ8 (alleles DQA1\*03/DQB1\*0302)
  - DQ2-/DQ8- (DQA1\*05 or DQB1\*02)
- COELIAC2 (5q31–33) Cytokines
- COELIAC3 (2q33) CTLA4
- COELIAC4 (19p13.1) myosin IXB (alters epithelial actin remodeling)
- GWAS- IL- 2 and IL- 21 (4q27)

### **Celiac Disease: Pathogenesis**



### Di Sabatino A, 2009

### **Celiac Disease: Pathogenesis**



Leonard MM et al, 2017

### **Celiac Disease: immunogenic Peptides**

## 33-mer LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (residues 57 to 89) it harbors six partly overlapping DQ2-restricted epitopes

DQ2.5-restricted epitopes	
DQ2.5-glia-αla	P F P Q P E L P Y
DQ2.5-glia-α1b	P Y P Q P E L P Y
DQ2.5-glia-α2	PQPELPYPQ
DQ2.5-glia-α3	FRPEQPYPQ
DQ2.5-glia-y1	P Q Q S F P E Q Q
DQ2.5-glia-y2	IQPEQPAQL
DQ2.5-glia-y3	QQPEQPYPQ
DQ2.5-glia-γ4a	SQPEQEFPQ
DQ2.5-glia-γ4b	PQPEQEFPQ
DQ2.5-glia-y4c	QQPEQPFPQ
DQ2.5-glia-y4d	PQPEQPFCQ
DQ2.5-glia-y5	QQPFPEQPQ
DQ2.5-glia-w1	I P F P Q P E Q P F
DQ2.5-glia-w2	PQPEQPFPW
DQ2.5-glut-L1	PFSEQEQPV
DQ2.5-glut-L2	FSQQESPF
DQ2.5-hor-1	PFPQPEQPF
DQ2.5-hor-2	PQPEQPFPQ
DQ2.5-hor-3	PIPEQPQPY
DQ2.5-sec-1	PFPQPEQPF
DQ2.5-sec-2	PQPEQPFPQ
DQ2.5-ave-1	PYPEQEEPF
DQ2.5-ave-1b	PYPEQEQPF
DQ8-restricted epitopes	
DQ8-glia-a1	EGSFQPSQE
DQ8-glia-yla	EQPQQPFPQ
DQ8-glia-y1b	EQPQQPYPE
DQ8-glut-H1	QGYYPTSPQ

### **Risk phenotypes**

- High risk: HLA-DQ2.5
  - Large peptide repertoire
  - Largely resistant to degradation
- Low risk: HLA-DQ8
   Small peptide repertoire
  - Less resistant to degradation
- Very low risk: HLA-DQ2.2
  - Very small peptide repertoire
  - Low resistance to degradation

### Shan L, 2002, Koning F, 2012

## Non Celiac disease Gluten Sensitivity (NCGS)

The clinical symptoms of nonceliac gluten sensitivity begin after the ingestion of gluten-containing grains.


Symptoms improve or disappear with withdrawal of these grains from the diet, and symptoms reappear after gluten challenge, usually within hours or days.

**Gastrointestinal presentation** of nonceliac gluten sensitivity is characterized by abdominal pain, bloating, bowel irregularity (diarrhea, constipation, or both),

**Extra-intestinal manifestations** include patient report of a "foggy brain," which is described as slowed thinking, memory disturbance, or reduced level of alertness, along with headache, joint and muscle pain, fatigue, depression, leg or arm numbness, dermatitis (eczema or skin rash), and anemia. Table 1. The clinical manifestations of Non-Celiac Gluten Sensitivity (NCGS

Frequency	Intestinal	Extra-Intestinal	
Very Common	Bloating	Lack of wellbeing	
	Abdominal pain	Tiredness	
Common	Diarrhea	Headache	
	Epigastric pain	Anxiety	
	Nausea	Foggy mind	
	Aerophagia	Numbness	
	GER	Joint/muscle pain	
	Aphthous stomatitis	Skin rash/dermatitis	
	Alternating bowel habits		
	Constipation		
Undetermined	Hematochezia	Weight loss	
	Anal fissures	Anemia	
		Loss of balance	
		Depression	
		Rhinitis/asthma	
		Weight increase	
		Interstitial cystitis	
		Ingrown hairs	
		Oligo or polymenorrhea	
		Sensory symptoms	
		Disturbed sleep pattern	
		Hallucinations	
		Mood swings	
		Autism	
		Schizophrenia	

## **NCGS diagnosis**



## Effectiveness of gluten free diet in NCGS patients

Author	# of patients	p
Cooper et al 1980	6	P<0.001
Biesiekierski et al 2011	34	P=0.047
Carroccio et al 2012	276	P<0.001
Di Sabatino et al 2015	61	P=0.047

## **Gluten sensitivity Non-celiac**

-34 patients (aged 29-59 years, 4 men) -completed 6 weeks of double blind placebo controlled gluten exposure

-. Overall, 56% had human leukocyte antigen (HLA)-DQ2 and/or HLA-DQ8.

-68% in the gluten group, reported that symptoms were not adequately controlled vs 40% on placebo (P=0.0001).

-On a visual analog scale, patients were significantly worse with gluten within 1 week for overall symptoms (P=0.047), pain (P=0.016), bloating (P=0.031), satisfaction with stool consistency (P=0.024), and tiredness (P=0.001).

-Anti-gliadin antibodies were not induced.

-There were no significant changes in fecal lactoferrin, levels of celiac antibodies, highly sensitive C-reactive protein, or intestinal permeability. -There were no differences in any end point in individuals with or without DQ2/DQ8.

Biesiekierski JR, 2011

## **Gluten sensitivity Non-celiac**

-36 patients (aged 29-61 years, 6 men) -completed 2 weeks of fermentable oligo-di-mono-saccharides and polyols (FODMAPs).

then

- -1 group did gluten free diet
- -1 group low gluten diet
- -1 group high gluten diet

All had similar increase of symptoms

Biesiekierski JR, 2011

FODMAPS: Fermentable –Oligosaccharides – Disaccharides –Monosaccharides –And Polyols

FODMAPs comprise:

-oligosaccharides, including fructans and galacto-oligosaccharides;

-disaccharides, including lactose;

-monosaccharides, including fructose; -polyols, including sorbitol, <u>xylitol</u>, and mannitol.

## FODMAPS: Fermentable –Oligosaccharides – Disaccharides –Monosaccharides –And Polyols

**Sources of fructans** wheat (although some wheat strains such as <u>spelt</u> contain lower amounts), <u>rye</u>, <u>barley</u>, <u>onion</u>, <u>garlic</u>, <u>Jerusalem</u> and <u>globe</u> <u>artichoke</u>, <u>asparagus</u>, <u>beetroot</u>, <u>chicory</u>, <u>dandelion leaves</u>, <u>leek</u>, <u>radicchio</u>, the white part of <u>spring onion</u>, <u>broccoli</u>, <u>brussels sprouts</u>, <u>cabbage</u>, <u>fennel</u> and <u>prebiotics</u> such as fructooligosaccharides (<u>FOS</u>), <u>oligofructose</u> and <u>inulin</u>]

**Sources of galactans** Pulses and beans are the main dietary sources (though <u>green beans</u>, tofu and tempeh contain comparatively low amounts **Sources of polyols** Polyols are found naturally in some fruit (particularly <u>stone fruits</u>), including <u>apples</u>, <u>apricots</u>, <u>avocados</u>, <u>blackberries</u>, <u>cherries</u>, <u>lychees</u>, <u>nectarines</u>, <u>peaches</u>, <u>pears</u>, <u>plums</u>, <u>prunes</u>, <u>watermelon</u> and some vegetables, including <u>cauliflower</u>, <u>mushrooms</u> and <u>mange-tout peas</u>. They are also used as <u>bulk sweeteners</u> and include <u>isomalt</u>, <u>maltitol</u>, <u>mannitol</u>, <u>sorbitol</u> and <u>xylitol</u>

**Fructose and lactose** People following a low-FODMAP diet may be able to tolerate moderate amounts of fructose and lactose, particularly if they have <u>lactase persistence</u>

# Eliminate foods containing fodmaps

excess fructose	lactose	fructans	galactans	polyols
fruit apple, mango, nashi, pear, tinned fruit in natural juice, watermelon sweeteners fructose, high fructose corn syrup large total fructose dose concentrated fruit sources, large serves of fruit, dried fruit, fruit juice honey corn syrup, fruisana	milk from cows, goats or sheep, custard, ice cream, yoghurt cheeses soft unripened cheeses eg. cotage, cream, mascarpone, ricotta	vegetables artichoke, asparagus, beetroot, broccoli, brussels sprouts, cabbage, eggplant, fennel, garlic, leek, okra, onion (all), shallots, spring onion cereals wheat and rye, in large amounts eg. bread, crackers, cookies, couscous, pasta fruit custard apple, persimmon, watermelon miscellaneous chicory, dandelion, inulin, pistachio	legumes baked beans, chickpeas, kidney beans, lentils, soy beans	fruit apple, apricot, avocado, blackberry, cherry, longon, lychee, nashi, nectarine, peach, pear, plum, prune, watermelon vegetables cauliflower, green capsicum (bell pepper), mushroom, sweet corn sweeteners sorbitol (420) mannitol (421) isomalt (953) maltitol (965) xylitol (967)

# Foods suitable on a low-fodmap diet

grain foods

### fruit

banana, blueberry, boysenberry, canteloupe, cranberry, durian, grape, grapefruit, honeydew melon, kiwifruit, lemon, lime, mandarin, orange, passionfruit, pawpaw, raspberry, rhubarb, rockmelon, star anise, strawberry, tangelo Note: if fruit is dried, eat in smal quantities

fruit



vegetables alfalfa, bamboo shoots, bean shoots, bok choy, carrot, celery, choko, choy sum, endive, ginger, green beans, lettuce, olives, parsnip, potato, pumpkin, red capsicum (bell pepper), silver beet, spinach, squash, swede, sweet potato, taro, tomato, turnip, yam, zucchini

vegetables

#### herbs

basil, chili, coriander, ginger, lemongrass, marjoram, mint, oregano, parsley, rosemary, thyme

#### cereals

gluten-free bread or cereal products

#### bread

100% spelt bread

### rice

oats

#### polenta

#### other

arrowroot, millet, psyllium, quinoa, sorgum, tapioca



### milk

lactose-free milk\*, oat milk\*, rice milk\*, soy milk\*

milk products

'check for additives

#### cheeses

hard cheeses, and brie and camembert

#### yoghurt

lactose-free varieties

ice-cream substitutes gelati, sorbet

butter substitutes olive oil

### tofu

### sweeteners

sugar\* (sucrose), glucose, artificial sweeteners not ending in '-ol'

other

### honey substitutes golden syrup\*, maple syrup\*, molasses, treacle

'small quantities



## Monash University "Low FODMAP Diet".

**Vegetables**: alfalfa, bean sprouts, green beans, bok choy, capsicum (bell pepper), carrot, chives, fresh herbs, <u>choy sum</u>, cucumber, lettuce, tomato, <u>zucchini</u>

Fruits: banana, orange, grapes, melon


Protein: meats, fish, chicken, tofu, tempeh

Dairy: lactose-free milk, lactose-free yoghurts, hard cheese

**Breads and cereals**: <u>gluten-free</u> bread and <u>sourdough</u> <u>spelt</u> bread, <u>crisped rice</u>, oats, gluten-free pasta, rice, <u>guinoa</u>

Biscuits (cookies) and snacks: gluten-free biscuits, rice cakes, corn thins **Nuts and seeds**: <u>almonds</u> (no more than 10 nuts per serving), pumpkin seeds **Beverage options**: water, <u>coffee</u>, <u>tea</u>

# Center for Pediatric Eosinophilic Disorders (CPED)




The largest clinical center in the world with over 1800 patients with EoE

## CHOP Accomplishments


- Identified the Genetic risk (TSLP, EMSY, CAPN14) factor for EoE
- Wrote the critical manuscript defining natural history
- Developed a new clinical test for food sensitivity in EoE
- Characterized efficacy of two treatment interventions
- Orchestrated the first multicenter consortium for EoE
- First clinical trial in Milk desensitization in the world (SMILEE)

# **EoE: Epidemiology**

## EoE prevalence 57/100,000







**1.** Dellon ES, et al. *Aliment Pharmacol Ther.* 2015;41:662-670. **2.** Hruz P. *Dig Dis.* 2014;32:40-47. **3.** Spergel JM, et al. *J Pediatr Gastroenterol Nutr.* 2009;48:30-36.

### **EoE definition**

#### **Clinicopathologic diagnosis**

- -Presence of clinical symptoms related to esophageal dysfunction
- •Dysphagia, vomiting, abdominal pain, heartburn, feeding difficulty, etc.
- -Isolated esophageal eosinophilia


EGDs

- •15 or more eosinophils per hpf in at least one esophageal biopsy
- •Histology of remainder of GI tract normal

#### DIAGNOSIS AND FOLLOW UP BASED ON REPETITIVE

Furuta, et al; Gastroenterology 2007; 133:1342.

### **Symptom Progression in EoE**



# Quality of Life EoE is reduced and improved with treatment

1) subject age, EoE symptom burden, atopic comorbidities, and treatment type were associated with base line quality of life ratings of child and family impact.

- 2) EoE symptom severity scores decreased during the study, although number of symptoms did not.
- 3) symptom burden scores were consistently correlated with Quality of life scores at baseline and follow-up time points.4) HRQoL improved during the course of evaluation and treatment, with

positive changes being strongest for patients with lower symptom severity at BL.

### Eosinophilic Esophagitis Long term follow up @ CHOP

• 1995-2006 (512 patients with EoE)

• Follow up to 14.2 yrs

× Average of 2.4 yrs with a total of 1782 biopsies

• No cases of EoE becoming Eosinophilic gastroenteritis

0 24 patients refused therapy or lost to F/U

- × Years since  $1^{st}$  visit  $6.2\pm3.6$
- × # eosinphils 1<sup>st</sup> EGD − 35.4±24.8
- × # eosinophils recent EGD − 39.1±27.9
- × 20/24 initially presented with GERD symptoms

• All returned with symptoms of dysphagia

### Is there a biomarker for EoE?

- Peripheral Biomarkers
  - FeNO, Eotaxin-3, Eosinophilic Proteins, Cytokines, Chemokines, siRNA, stool samples-none identified yet.

- Molecular Signature—Rothenberg Lab
  - Group of genes can distinguish EoE (But still need a biopsy)
    - 1607 significantly dysregulated transcripts (1096 upregulated, 511 downregulated) on RNA seq (Sherrill et al. Genes Immunity 2014)
    - × 96 gene panel (EDP) –Wen et al. Gastro 2013

### **Do Symptoms match Histology?**

Table 4. Accuracy of Patient-Reported Clinical Symptoms (Assessed Using EEsAI PRO Score) to Detect Histologic Remission

EEsAI PRO score cutoff	Cumulative remission, <sup>a</sup> n (%)	Cumulative frequency, <sup>b</sup> n (%)	PPV, %	NPV, %	Sensitivity, %	Specificity, %	Accuracy, %
Histologic remission: peak count of							
<20 eosinophils/mm <sup>2</sup>							
15	38/96 (39.6)	96/269 (35.7)	39.6	78.6	50.7	70.1	64.7
20	42/111 (37.8)	111/269 (41.3)	37.8	79.1	56.0	64.4	62.1
25	42/112 (37.5)	112/269 (41.6)	37.5	79.0	56.0	63.9	61.7
30	51/162 (31.5)	162/269 (60.2)	31.5	77.6	68.0	42.8	49.8
35	54/180 (30.0)	180/269 (66.9)	30.0	76.4	72.0	35.1	45.4
Histologic remission: peak count of <60 eosinophils/mm <sup>2</sup>							
15	49/96 (51.0)	96/269 (35.7)	51.0	70.5	49.0	72.2	63.6
20	54/111 (48.6)	111/269 (41.3)	48.6	70.9	54.0	66.3	61.7
25	54/112 (48.2)	112/269 (41.6)	48.2	70.7	54.0	65.7	61.3
30	68/162 (42.0)	162/269 (60.2)	42.0	70.1	68.0	44.4	53.2
35	71/180 (39.4)	180/269 (66.9)	39.4	67.4	71.0	35.5	48.7

NOTE. Data for 5 different cutoff values of EEsAI PRO score are shown.

NPV, negative predictive value; PPV, positive predictive value.

<sup>a</sup>Number of patients in histologic remission for a given EEsAI PRO score cutoff value.


<sup>b</sup>Number of natients with a given FFeAI PRO score below the cutoff value

#### Safroneeva et al. Gastro 2016

### **Atopy in EoE**

#### Large concomitant atopy up to 80% in Pediatrics and Adults


	Number of patients with EoE	Atopy	Asthma	Allergic Rhinitis	Atopic dermatitis	IgE specific for foods	Anaphylaxis to foods
General population	NA	30%	8.5%	25%	10%	10%	0.2%
Spergel et al. Philadelphia	620	NA	50%	61%	21%	50	10%
Assa'ad et al. Cincinnati	89	79%	39%	30%	19%	75%	NA
Sugnanam et al. Australia	45	NA	66%	93%	55%	NA	24%
Guajardo et al. World registry	39	80%	38%	64%	26%	62%	23%








Hill DA 2018



#### Maggadottir SM JACI 2014

#### Children with IgE - FA are at risk of developing EoE



Characteristic	Odds ratio	95% CI	P value
Gender			
Male vs Female	2.27	1.89-2.78	<.0001
Race			
White vs Black	1.99	1.55-2.56	<.0001
Ethnicity			
Hispanic vs Non-Hispanic	0.99	0.67-1.47	ns
Specific food allergens			
Peanut	1.07	0.90-1.27	ns
Egg	2.27	1.91-2.64	<.0001
Tree nut	1.04	0.88-1.23	ns
Milk	4.19	3.52-4.97	<.0001
Shellfish	1.55	1.24-1.92	<.0001
Number of food allergies			
2 foods	2.93	2.16-4.05	<.0001
3+ foods	5.29	3.82-7.32	<.0001

EMR, Electronic medical record; EoE, eosinophilic esophagitis; ns, nonsignificant.


#### Hill DA 2017

#### Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis



Alfredo J. Lucendo, MD, PhD, FEBGH \*; Ángel Arias, BSc, MSc<sup>†</sup>; and José M. Tenias, MD, PhD<sup>†</sup>

\*Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Ciudad Real, Spain <sup>†</sup>Research Unit, Complejo Hospitalario La Mancha Centro, Alcázar de San Juan, Ciudad Real, Spain



Lucendo et al. Annales of Allergy 2014

Interventions	Incidence	n
EoE after immunotherapy (overall) Subgroups according to quality (type of publication)	2.72% (1.7-4)	9
Medium to high (full-length article) Low (abstract)	3.51% (1.3-6.7) 2.5% (1.3-4)	3 6

#### **Outgrowing EoE**

### 1995-2006 (512 patients with EoE)

	Total Resolution	Outgrown Some Food Allergies
Ν	11	33
Age at Diagnosis (yr)	5.6 yr	4.9 yr
Follow-up (yr)	5.2yr	6.8 yr

Spergel et al. JPGN 2009

### **Genetic Factors in EoE**

**Male 3:1** 

#### General population



#### Siblings



2.4%



Twin





0.06% 40 times

#### 683 times

#### Sibling Risk in Asthma==2

Alexander et al. J Allergy Clin Imi






### Food Allergy and EoE: lesson learned from elemental diet

### Kelly and Sampson

- 10 patients (5 yr, range: 8 mo-12.5 yr)
- Endoscopy pre- & post-trial

Kelly et al. Gastroenterology 1995

Kelly et al, 1995 0.90 (0.55. 1.00) De Agustín et al. 2002 .00 (0.16, 1.00) Liacouras et al, 2005 ,98 (0,94, 0,99) Ferreira et al, 2008 ,00 (0,03, 1,00) Hiremath et al. 2010 0.62 (0.32, 0.86) Abu-Sultaneh et al. 2011 0.00 (0.00, 0.98) Basilious et al, 2011 .00 (0.16. 1.00) Pascual et al. 2011 1.00 (0.29, 1.00) Henderson et al. 2012 0.96 (0.86 1.00) Kagalwalla et al, 2012 0.83 (0.52, 0.98) Spergel et al. 2012 0,95 (0,91, 0,98) Peterson et al. 2012 0.94 (0.73, 1.00) Al-Hussaini et al. 2013 1.00 (0.29, 1.00) 0,91 (0,85, 0,95) combined 0.50 0.75 0.00 12=52.3% proportion (95% confidence interval)



#### Lucendo, 2015

### How to predict the food implicated in food allergy driven EoE

- History not accurate

   -doesn't predict level of inflammation
   -Reactions may be delayed and persist several days
   -More than one food can cause reaction
- Percutaneous Testing for most common foods

   Strong NPVs (Negative predictive value) (NOT FOR MILK)
   Low PPVs (Positive predictive values) 50-85% 9depending for which food
- IgE Microarray (CRD)-based dietary treatment was not effective in adult patients with EoE
  - -missed sensitizations
  - -limited relevance of IgE in the
  - -pathophysiology of EoE

Kelly, et al, Gastroenterology 1995 Liacouras et al Clin Gastroenterology and Hepatology 2005 Spergel JACI 2007



Van Rhijn BD JACI 2015



### **Percutaneous Testing**


- Variable predictive
- Low NPV and PPVs 50-85%
- Low sensitivity
- Cross-reactivity between foods

• Clinical significance?

		SPT			
Food	PPV	NPV	Specificity	Sensitivity	
Milk (n = 46)	95.7%	57.7%	42.3%	97.6%	
Egg $(n = 39)$	84.8%	75.4%	65.1%	90.2%	
Soy $(n = 28)$	70.0%	68.9%	37.8%	89.5%	
Wheat $(n = 26)$	77.8%	64.7%	18.9%	96.5%	
Corn (n = 26)	57.1%	71.3%	13.8%	95.4%	
Beef $(n = 23)$	81.8%	74.7%	30.0%	96.9%	
Chicken $(n = 15)$	50.0%	83.3%	26.3%	93.3%	
Rice $(n = 14)$	50.0%	85.6%	13.3%	97.5%	
Potato $(n = 11)$	60.0%	89.9%	25.0%	97.6%	
Peanut $(n = 10)$	77.8%	97.6%	77.8%	97.6%	
Oat $(n = 9)$	33.3%	90.1%	10.0%	97.6%	
Barley $(n = 9)$	42.9%	90.8%	27.3%	95.2%	

NPV = negative predictive value; PPV = positive predictive value.

### IgE Microarray (CRD) fail to identify trigger foods in EoE



van Rhijn BD JACI 2015

### Six Food Elimination Diet (SFED) Adults

#### • Food Reintroduction

most common food triggers were wheat (60%)

Milk (50%),


soy (10%),

nuts (10%),

egg (5%).

seafood (o)

- Three patients had more than one food trigger
- SPT accurately predicted only 13% of causal agents, and 67% of patients who had a food trigger identified by the reintroduction process had a negative SPT to all foods



Gonsalves et al. Gastroenterology 2012

Soy

Egg

Milk


Seafood

10/50 (20%)

6/50 (12%)


6/50 (12%) 3/50 (6%)

### SFED and EoE



Lucendo, Curr Gastroenterol Rep.2015

#### Four Food Elimination Diet (Milk, wheat, egg, legumes) Adults




DISTAL

#### **TABLE II**. Food triggers identified by sequential food challenge (n = 22) after response to the FFGED

A single causative food group	10/22	45%
Milk	6/22	27%
Wheat	3/22	13%
Egg	1/22	4%
Two causative food groups	10/22	45%
Milk and egg	2/22	9%
Milk and legumes	2/22	9%
Milk and wheat	1/22	4%
Wheat and egg	3/22	13%
Egg and legumes	2/22	9%
Three or more causative food groups	0	0
No causative food group	2/22	9%

#### Molina-Infante, JACI 2015

### One Food Elimination Diet (Milk) children



Kruszewski PG et al, Dis Esophagus 2015



Reintroduction of 1 single food every 6-12 weeks followed by EGD Elimination of 1 single food (from the 6 food elimination pool) every 6-12 weeks followed by EGD

#### **GOAL = Find the least restrictive diet that can control EoE**

#### **Most Common Foods in EoE**

Food	Causative foods, %
Milk	17
Egg	11
Wheat	9.6
Soy	7.8
Corn	7.8
Beef	6.6
Chicken	6.1
Peanut	5.4
Potato	4.8
Rice	4.1

**TABLE 3.** The 10 most common foods confirmed by endoscopy after allergy testing

### **Most Common Foods in EoE**


All pts had > 20 eos/hpf on GERD and AR medication and had

-Removal of a single food leading to normal esophageal biopsy (0 eosinophils/HPF).

-Addition of a single food leading to increased esophageal eosinophils on biopsy after a previously normal biopsy.


319 Children had definitive causative food (out of 941 patients examined)

Food	No. of subjects
Milk	78
Milk, meats*	24
Milk, egg, wheat, soy	20
Milk, soy	15
Grains*	13
Milk, egg, wheat, meats	11
Egg, wheat	10
Milk, egg	8
Milk, egg, wheat	8
Egg	8
Soy	7
Wheat	5



Spergel et al JACI 2012009

# Some patient with milk induced EoE are able to tolerate baked milk




FIGE1. Median peak eosinophil count/hpf at different time points.

#### Leung J, JACI 2013

Baked milk tolerant

Baked milk reactive

#### Baked Milk/Egg allergen



It is well known that cooking and/or processing can

- denature conformational epitopes, making them no longer recognizable by the epitope-specific IgE.

-strengthen certain protein bonds or create neoepitopes, such as when amino acids react with aldehyde or ketone groups on sugars (glycation) in enzymatic browning or roasting known as the Maillard reaction. (roasting peanuts or cooking shellfish) Peanut protein component Ara h2 forms aggregates during this reaction that are harder to digest and more easily recognized by epitope-specific IgE.

-The predominant protein in Egg White, ovalbumin (OVA), is a conformational epitope and heat labile, whereas the other major allergen, OM, is a sequential epitope and heat resistant, making OM potentially more allergenic.

-The whey proteins in CM, such as alpha-lactalbumin and beta-lactoglobulin, contain conformational epitopes that are heat labile (significantly reduced after 20 minutes of boiling), whereas casein contains mostly sequential and heat-resistant epitopes

#### Baked Milk/Egg allergen: Matrix effect




- Heating is only one part of rendering baked milk and egg less allergenic. Interactions with proteins, fats, or sugar in a food matrix, such as wheat, are equally important.
- This is why the simple act of boiling cow's milk may not be enough to decrease allergenicity to a degree comparable with a baked product.
- The food matrix may help to reduce exposure of the specific proteins to the immune system.
- For example, the beta-lactoglobulin fractions of whey form disulfide bonds with the other proteins in the food matrix, making them less recognizable by specific IgE.
- Ovomucoid polymerizes with proteins in the food matrix, such as gluten, to form large insoluble aggregates, making it less recognizable by epitope-specific IgE and potentially less allergenic

#### Rostrum

#### Should wheat, barley, rye, and/or gluten be avoided ( in a 6-food elimination diet?






#### Gluten-containing Grains Eliminated on 6FED for EoE

There is clearly some uncertainty about the necessity of avoiding rye and barley in addition to wheat in elimination diets in adults and children with EoE. Published and unpublished data from our centers and others (including studies of patients with EoE and gluten-triggered celiac disease) are too limited to speculate whether total gluten elimination (wheat, barley, and rye) might be meaningfully more efficacious than elimination of only wheat in patients with EoE. Unless the theoretic risks of wheat, barley, and rye cross-reactivity/cross-contamination are confirmed with empiric evidence in patients with EoE, we advise against extending wheat elimination to include the exclusion of other gluten-containing grains

#### **JACI**, 2016



### **Pharmacologic Therapy**

### **Systemic Steroids** – effective at improving symptoms and histology of EoE in 95% of pts

- Upon discontinuation, 90% had recurrence of symptoms
- *(Long term use) Side effects*: bone abnormalities, poor growth, adrenal suppression
- May be needed short term for extreme cases


**Topical/swallowed Steroids** – less toxic to pt while still 50-85% effectiveAfter administration of topical steroids no food or drink is allowed for 30 minutes

- Accepted EoE treatment in adults and children.
- Upon discontinuation almost all patients have a recurrence of symptoms
- Often, large doses needed
- Side effects: esophageal candidiasis
- Potential: growth impairment and osteoporosis
- Aerosolized fluticasone propionate from a metered dose inhaler (no spacer) 110 mcgX 2 puffs twice daily for children year< 8 years of age;220 mcg X 2 puffs twice daily for children year>8 years of age
- Budesonide is delivered as viscous budesonide, is made by mixing each 1 mg Pulmicort RespuleTM with 10 g (10 packets) of sucralose (SplendaTM) to create a volume of approximately 8mL .0.5-2mg in 1 or 2 dived doses

Liacouras *et al*. Clin Gastroenterol Hepatol 2005 Furuta *et al*. Gastroenterology 2007 Cianferoni a et al 2015


### PPI-Responsive EOE PPI-REE Estimates

Author	Year	Populatio n	Design	# Patients	%
Dranove	2009	Pediatric	Retro	43	40
Sayej	2009	Pediatric	Retro	36	39
Monte- Infante	2011	Adult	Prospective	35	74
Peterson	2010	Adult	RCT	12	33
Moawad	2011	Adult	RCT	20	35
Dellon	2013	Adult	Prospective	65	37
Schroeder	2013	Adult	Retro	7	71



Dranove et al J Ped 2009

## Which are the cells that produce Th2 cytokines in EoE?




(Strauman AJ Allergy Clin Immunol 2001;108:954-61.)

<b>Cytokines in E</b> Publication	<b>oE pathogenesis</b> Human Cytokine Finding
(	•Increased expression of IL-5
Straumann et al JACI 2002	TNF-a was increased in epithelial cells
Straumann et al.	Eosinophils express "activation" markers: 60% express <b>IL-13 and IL-4</b>
Inflamm Bowel Dis, 2004	41% of intestinal eosinophils express IL-13 at baseline, circulating eosinophils do not express IL-4 or -13
Gupta et al. Am J Gastro 2006	No increase in cysLT
Blanchard et al. J Clin Invest 2006	50-fold increase in <b>Eotaxin-3</b> in biopsy
Aceves et al. JACI 2007	Esophageal remodeling with increased TGFb, phospho-Smad2/3, VCAM
Battacharya et al, Hum Pathol 2007	Increased Eotaxin-3 in archived biopsies
Blanchard C et al JACI 2011	Increased <b>IL-13</b> , <b>IL-4</b> , <b>IL-5 IL-15</b> in esophageal bx of patients with active EoE
Zhou H et al Gastroenterology 2010	Eosinophialia in Esophageal bx correlates with IL-15 levels
Rothenberg ME, Spergel JM, Nat Genet. 2010	Increased TSLP in esophageal bx of patients with active EoE

### Anti-IL-5 EoE

•Anti- IL-5 (mepolizumab/reslizumab) reduces Eosinophilic infiltration in humans but has no significant effects on dyshpagia



#### Allergy

#### EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY



Allergy

#### REVIEW ARTICLE

#### Eosinophilic esophagitis is characterized by a non-IgEmediated food hypersensitivity<sup>§</sup>

D. Simon<sup>1,\*</sup>, A. Cianferoni<sup>2,3,\*</sup>, J. M. Spergel<sup>2,3</sup>, S. Aceves<sup>4</sup>, M. Holbreich<sup>5</sup>, C. Venter<sup>6,7</sup>, M. E. Rothenberg<sup>6</sup>, I. Terreehorst<sup>8</sup>, A. Muraro<sup>9</sup>, A. J. Lucendo<sup>10</sup>, A. Schoepfer<sup>11</sup>, A. Straumann<sup>12</sup> & H.-U. Simon<sup>13</sup>

1) The detection of specific IgEs for food allergens, either by SPT or by specific sera IgE (sIgE), has not proven successful for the identification of causative foods in EoE

2) Clinical trials and case series have shown that therapy with omalizumab is not effective in inducing remission of EoE.


3) Oral immunotherapy, which has been used successfully in IgE-mediated food allergy, is associated with an increased risk of developing EoE (e.g. in 2 to 10% of treated patients)

4) Children who outgrow IgE-mediated food allergy and therefore are able to reintroduce these foods in their diet can later develop EoE to the same food.
5) In experimental models in which food allergens are able to induce an EoE-like disease, mice with depleted IgE and devoid of mast cells still could develop esophageal inflammation and consequent food impaction similar to the wild-type mice .

Simon D, Cianferoni A et al Allergy

#### 2016

## In animal model EoE is Non IgE mediated food allergy



Noti et al, Nat. Medicine 2013

### **EoE** ≠ **IgE Mediated Disease**

	Omalizumab	Placebo
Number of subjects	16	14
Eosinophils/high-power field, before treatment	41 ± 17	37 ± 9
Eosinophils/high-power field, after treatment	39 ± 15	33 ± 12
Change in mean eosinophil content	-1.3	-4.2
Dysphagia score before treatment	$4.0 \pm 0.7$	$5.5 \pm 0.5$
Dysphagia score after treatment Change in dysphagia score after treatment	2.8 ± 1.0 -1.2"	3.8 ± 0.6 -1.7"

In a double blind placebo control trial Omalizumab Has No Effect on Eosinophil Content or ,Relative to Placebo Controls, Symptoms

Table 2. Esophageal Mucosal Tissue IgG4 Is Strikingly and Specifically Increased

	Normal controls	Eosinophilic esophagitis	Eosinophilic esophagitis/control ratio
IgM, mg/g protein	0.16 ± 0.07	0.38 ± 0.21	2.4 (0.91–5.5)
IgA, mg/g protein	0.32 ± 0.15	0.51 ± 0.18	1.6 (0.84-3.5)
IgG1, mg/g protein	$2.2 \pm 0.73$	3.1 ± 1.1	1.4 (0.78-2.4)
IgG2, mg/g protein	$0.76 \pm 0.14$	$1.4 \pm 0.64$	1.8 (0.88-2.9)
IgG3, mg/g protein	$0.10 \pm 0.05$	0.15 ± 0.092	1.5 (0.48-3.7)
IgG4, mg/g protein	0.029 ± 0.013	1.3 ± 0.99 <sup>a</sup>	45 (7.5–109)
IgG4, % total IgG	$0.92 \pm 0.43$	17 ± 7.7ª	18 (8.4–40)


#### Clyaton F 2014

### EoE ≠ IgE Mediated Disease

Immunoglobulin, median (IQR)	Control subjects	Subjects with EoE	EoE/control ratio	P value <sup>b</sup>
IgE	19.5 (18.8-20.4)	18.7 (18.2-19.1)	1.0	.0620
IgA	0.9 (0.5-1.4)	2.0 (1.8-4.6)	2.2	<.0001
lgM	0.9 (0.6-1.5)	2.3 (0.9-3.9)	2.6	.0102
lgG1	9.0 (6.6-10.2)	13.4 (9.5-18.4)	1.5	.0132
lgG2	8.1 (2.7-11.2)	16.2 (9.7-32.6)	2.0	.0122
lgG3	0.6 (0.5-1.0)	2.2 (1.3-5.1)	3.7	<.0001
lgG4	0.2 (0.1-0.9)	4.2 (1.0-13.1)	21.0	<.0001
lgG4, % total IgG	4.5% (1.8-9.3)	18.0% (6.5-23.5)	4.0	.0122


Rosenberg CE, Allergy 2018

### IgG4 specific for some foods maybe important, but their clinical value is to be determined



Clayton et al Gastroenterology 2014

### IgG4 AND EOE



• Esophageal IgG4 levels are increased in patients with EoE compared with control individuals and strongly correlate with


esophageal eosinophil numbers and multiple features of histological grade and stage scores.

• Esophageal IgG4 protein levels correlate with multiple components of the disease as assessed by transcriptome profiling, including IL4, IL13 and IL10 mRNA expression levels.

• IgG4 heavy chain mRNA expression is proportional to IgG4 protein levels and IL10 mRNA expression levels in the esophagus of patients with EoE..


#### IgG4 to cow's milk protein in EoE

**GRAPHICAL ABSTRACT** 



Schuyler AJ et al JACI 2018


#### IgG4 to cow's milk protein in EoE



**FIG 2**.  $slgG_4$  levels (geometric mean [95% CI]) to Bos d 4, Bos d 5, and Bos d 8 in 71 patients with EoE and 210 control subjects with or without CM sensitization. *Values below the dotted line* indicate the number not detectable (#ND) and were excluded from calculation of the geometric mean. Statistical analysis was performed with the Mann-Whitney test.

Schuyler AJ et al JACI 2018

#### IgG4 to cow's milk protein in EoE




**FIG 4**.  $slgG_4$  levels to Bos d 4, Bos d 5, and Bos d 8 in patients with EoE before and after a 6- to 8-week CM elimination diet (n = 13) compared with baseline levels in control subjects (n = 210). Statistical analysis was performed with the Wilcoxon matched pair test and the Mann-Whitney test.

Schuyler AJ et al JACI 2018

Can slgG<sub>4</sub> levels to CM be useful as a biomarker for the diagnosis or monitoring of EoE?.

- Need prospective investigation,
- Large overlapping between normal and EoE
- the difference in ORs between girls and boys reported here suggests that this question should be addressed with consideration to sex.

# IgG4 and EoE Food allergy in adults




Wright et al. 2016

### IgG4 Are they pathogenetic?

- slgG₄is not sufficient as to cause EoE is supported by the fact that 10% of control subjects also had high-titer slgG₄to CM proteins
- CM slgG₄is an epiphenomenon in patients with EoE, perhaps related to an aberrant T<sub>H</sub>2 or regulatory T-cell response.
- A pathogenic role for IgG<sub>4</sub> cannot be dismissed
- IgG₄ could be pathogenic by forming extracellular immune complexes, due to sIgG₄ antibody levels largely restricted to a single allergen (group) in presence of high concentrations of allergen in the tissue before Fab arm exchange occurred. Indeed sIgG₄ levels to CM proteins contributed more than 10% of total IgG₄ in 35% of our patients with EoE.
- Taken together, the question of whether high-titer slgG₄is an epiphenomenon or is mechanistically involved in the inflammation seen in patients with EoE is an important area for future inquiry.
- B-cell class-switch recombination (CSR) to IgG4 like the IgE one is induced by IL-4 and IL-13. IgG4 has also been associated with high levels of IL-10 secreted from regulatory B and T cells
- Patients with EoE have increased levels of TGF-b1 localized to eosinophils and mast cells in the esophagus. TGF-b1 can suppress IgE CSR and also promote mast cell accumulation and eosinophil survival.
- T cell play a central role in thus upstream defects in T-cell activation or development could contribute to both the pathology and IgG4 production in patients with EoE

# The IgE: IgG4 conundrum




#### In Eosinophilic Esophagitis:

1. IgG4 to food proteins is increased – but role in pathophysiology of disease is unclear

### Genetic Studies EoE

- Candidate Gene
- Genomic Wide Association Studies

	TSLP SNP	5q.22.1
	TSLP-R SNP	Xp22.3; Yp11.3
NON CO	Eotaxin 3	7q11.23
	CAPN14	2q.23
	EMSY	11q13.5



#### medicine

#### Common variants at 5q22 associate with pediatric eosinophilic esophagitis

Marc E Rothenberg<sup>1,11</sup>, Jonathan M Spergel<sup>2,3,11</sup>, Joseph D Sherrill<sup>1,11</sup>, Kiran Annaiah<sup>4,11</sup>, Lisa J Martin<sup>5,11</sup>, Antonella Cianferoni<sup>2,3</sup>, Laura Gober<sup>2</sup>, Cecilia Kim<sup>4</sup>, Joseph Glessner<sup>4</sup>, Edward Frackelton<sup>4</sup>, Kelly Thomas<sup>4</sup>, Carine Blanchard<sup>1</sup>, Chris Liacouras<sup>3,6</sup>, Ritu Verma<sup>3,6</sup>, Seema Aceves<sup>7</sup>, Margaret H Collins<sup>8</sup>, Terri Brown-Whitehorn<sup>2,3</sup>, Phil E Putnam<sup>9</sup>, James P Franciosi<sup>9</sup>, Rosetta M Chiavacci<sup>4</sup>, Struan F A Grant<sup>3,4,10</sup>, J Pablo Abonia<sup>1</sup>, Patrick M A Sleiman<sup>4</sup> & Hakon Hakonarson<sup>3,4,10</sup>

#### genetics

Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease

Leah C Kottyan<sup>1-3,13</sup>, Benjamin P Davis<sup>3,13</sup>, Joseph D Sherrill<sup>3</sup>, Kan Liu<sup>3</sup>, Mark Rochman<sup>3</sup>, Kenneth Kaufman<sup>1,2</sup>, Matthew T Weirauch<sup>1,4</sup>, Samuel Vaughn<sup>1</sup>, Sara Lazaro<sup>1,2</sup>, Andrew M Rupert<sup>4</sup>, Mojtaba Kohram<sup>4</sup>, Emily M Stucke<sup>3</sup>, Katherine A Kemme<sup>3</sup>, Albert Magnusen<sup>1,2</sup>, Hua He<sup>5</sup>, Phillip Dexheimer<sup>4</sup>, Mirna Chehade<sup>6</sup>, Robert A Wood<sup>7</sup>, Robbie D Pesek<sup>8</sup>, Brian P Vickery<sup>9</sup>, David M Fleischer<sup>10</sup>, Robert Lindbad<sup>11</sup>, Hugh A Sampson<sup>6</sup>, Vincent A Mukkada<sup>12</sup>, Phil E Putnam<sup>12</sup>, J Pablo Abonia<sup>3</sup>, Lisa J Martin<sup>5</sup>, John B Harley<sup>1,2,14</sup> & Marc E Rothenberg<sup>3,14</sup>

#### ARTICLE

Received 18 Jul 2014 | Accepted 16 Oct 2014 | Published 19 Nov 2014

DOI: 10.1038/ncomms6593

### GWAS identifies four novel eosinophilic esophagitis loci

Patrick M.A. Sleiman<sup>1,2</sup>, Mei-Lun Wang<sup>2,3</sup>, Antonella Cianferoni<sup>2,4</sup>, Seema Aceves<sup>5</sup>, Nirmala Gonsalves<sup>6</sup>, Kari Nadeau<sup>7</sup>, Albert J. Bredenoord<sup>8</sup>, Glenn T. Furuta<sup>9</sup>, Jonathan M. Spergel<sup>2,4</sup> & Hakon Hakonarson<sup>1,2</sup>

#### Thymic stromal lymphopoietin–elicited basophil responses promote eosinophilic esophagitis

Mario Noti<sup>1,227</sup>, Elia D Tait Wojno<sup>1,227</sup>, Brian S Kim<sup>1-3</sup>, Mark C Siracusa<sup>1,2</sup>, Paul R Giacomin<sup>1,24</sup>, Meera C Na<sup>1,25</sup>, Jalin J Benitze<sup>5</sup>, Kahry R Baymann<sup>7</sup>, Amanda B Mair<sup>6</sup>, David A Hill<sup>1,37</sup>, Kudakwaahe R Chikwawa<sup>8</sup>, Amin E Moghaddam<sup>9</sup>, Qaentin J Sattentau<sup>9</sup>, Aneesh Alex<sup>10-13</sup>, Chao Zhau<sup>10-12</sup>, Jennifer H Yarely<sup>13</sup>, Paul Menned Kather<sup>14</sup>, Masato Kabol<sup>316</sup>, Kozushigo Obata-Ninomiya<sup>17,18</sup>, Hajime Karasuyama<sup>27,18</sup>, Michael R Comeau<sup>19</sup>, Ter Brown-Wiktowri, Rene de Waal Malefyt<sup>20</sup>, Patrick M Sleiman<sup>21-23</sup>, Jiakon Hakonarson<sup>21-23</sup>, Antonella Chaffeoni<sup>7</sup>, Gary W Falk<sup>14,34,25</sup>, Mei-Luu Wang<sup>26,24,23</sup>, Jonathan M Spergel<sup>2,7,34,25</sup> & David Artis<sup>12,32,42</sup>

# **TSLP: Thymic stromal lymphopoietic**

•IL-7–like cytokine

- •Expressed in thymus and epithelial cells
- Potent inducer maturation of dendritic cells
- •Primes TH cells into TH2 cells
- •Induced by virus, bacterial, allergen

•TSLP is ↑ in lesional skin in AD and asthma.
•TSLP gene variant is associated with asthma and airway hyper-responsiveness. J. Allergy Clin. Immunol. 124, 222–229 (2009)






#### medicine

## Thymic stromal lymphopoietin–elicited basophil responses promote eosinophilic esophagitis

Mario Noti<sup>1,2,27</sup>, Elia D Tait Wojno<sup>1,2,27</sup>, Brian S Kim<sup>1-3</sup>, Mark C Siracusa<sup>1,2</sup>, Paul R Giacomin<sup>1,2,4</sup>, Meera G Nair<sup>1,2,5</sup>, Alain J Benitez<sup>6</sup>, Kathryn R Ruymann<sup>7</sup>, Amanda B Muir<sup>6</sup>, David A Hill<sup>1,2,7</sup>, Kudakwashe R Chikwava<sup>8</sup>, Amin E Moghaddam<sup>9</sup>, Quentin J Sattentau<sup>9</sup>, Aneesh Alex<sup>10–12</sup>, Chao Zhou<sup>10–12</sup>, Jennifer H Yearley<sup>13</sup>, Paul Menard-Katcher<sup>14</sup>, Masato Kubo<sup>15,16</sup>, Kazushige Obata-Ninomiya<sup>17,18</sup>, Hajime Karasuyama<sup>17,18</sup>, Michael R Comeau<sup>19</sup>, Terri Brown-Whitehorn<sup>7</sup>, Rene de Waal Malefyt<sup>20</sup>, Patrick M Sleiman<sup>21–23</sup>, Hakon Hakonarson<sup>21–23</sup>, Antonella Cianferoni<sup>7</sup>, Gary W Falk<sup>14,24,25</sup>, Mei-Lun Wang<sup>6,24,25</sup>, Jonathan M Spergel<sup>2,7,24,25</sup> & David Artis<sup>1,2,24–26</sup>




#### Basophil and TSLP dependent

 Food impaction

 Control IgG
 Anti-TSLP
 Anti-CD200R3

 4/14 (29%)
 0/9 (0%)
 0/8 (0%)



# RS3806932 TSLP SNP is associated with multiple food allergy in EoE

381 biopsy confirmed pediatric EoE patients.


TSLP Risk Allele	Odds Ratio	Standard	P value	95% Confidence
(homozygous/heterozygous)		Error		Interval
≥ 2 EoE food allergen triggers	4.616825	1.626283	<0.0001	2.314763-9.208321
Asthma	0.8805519	0.3394478	0.741	0.4136391-1.874513
AR	1.1322	0.496835	0.777	0.4790672-2.675775
AD	0.6805757	0.2524066	0.299	0.3289952-1.407873
IgE-FA	0.6867766	0.2398334	0.282	0.3463875-1.36166
Any Atopic Disease	1.653602	1.126703	0.460	0.4349646-6.286487
Male Gender	1.037716	0.2626875	0.884	0.6318373-1.704322

Fahey et at Clinical and Translational Gastroenterology 2018

### CALPAIN 14 (CAPN14)


2 independent GWAS identified SNP at 2p23 as risk factor for EoE CAPN14 is a functional proteases CAPN14 is increased in the biopsies of patients with active EoE Th2 Cytokines induce CAPN14 expression CAPN14 induces loss of epithelial cell architecture and barrier function CAPN14 reduces Desmoglein 1 (DSG1) expression Sleiman P et al 2014, Kattyan LC et al 2014, Davis BP et al 2016

### Calpain 14 a proteasis and Th2 Inflammation Epithelial damage





**Kottyan 2014 Nature Genetics** 

### **EoE pathogenesis**




Cianferoni A, 2015





Cianferoni et al JACI submitted


In patients with milk induced EoE T cell were activated to produce IL-5cytokines by milk antigens



Cianferoni et al JACI submitted

# Dupilumab (Anti-IL4R) in EoE


Dupilumab significantly reduced SDI PRO score at Week 10




# Th2 cytokines and epithelial dysfunction

# Th2 Inflammation and Epithelial damage

С







d

**Kottyan 2014 Nature Genetics** 

### **Calpain 14 and Barrier dysfunction**




### **Esophageal Epithelial barrier**




Multilayered stratified nonkeratinized quamous epithelium composed of the:

- stratum granulosum,
- stratum spinosum,
- stratum germinativum (i.e. basal layer; fig. 2).



- Tight junctions (occludins and claudins 1-4)
- .Adherent junctions (E-cadherin).
- Desmosomes (desmogelin and desmocollin )

### **EoE pathogenesis**



### Conclusions

- Eosinophils are part of the inflammatory cells typical of Th2 inflammation, but are not essential for pathogenesis
- A dysfunctional epithelium in atopic genetically susceptible individuals induce local atopic inflammation by
- Secreting mediators that promote Th2 cytokines
- Increase access to antigens
- Inducing local sensitization to allergen such as foods
  - Promote chronic inflammation

### **FPIES: Food protein enterocolitis**

FPIES is a non-IgE-mediated food allergy hallmarked by delayed onset of profuse, repetitive emesis, and lethargy that may be accompanied or followed by watery/bloody diarrhea

International Consensus Guidelines AAAAI. A Nowak- Węgrzyn, et al (Submitted)

### **Clinical features of FPIES**

- Vomiting (typically around 2 hours post ingestion)
- Diarrhea (typically 5 hours post ingestion)
- Lethargy
- Dehydration that may progress to:
  - o Acidemia
  - Hypotension
  - o Methemoglobinemia
- May also find elevated PMN/PLTs count
- Occasional hypoalbuminemia and FTT



### Treatment of acute reaction

- Intravenous fluid boluses
- Ondasetron
- Steroids
- Supportive care
- Epinephrine traditionally does NOT help



Allergy testing for food specific IgE by either prick skin testing or serologic assessment is typically of little or no value in the diagnosis of FPIES, as FPIES is not an IgEmediated process.


Atopy patch testing (APT) has also been evaluated as a possible means of identifying specific food sensitivities in patients with FPIES.

However, only two studies performed to date have evaluated APT, with conflicting results as to its diagnostic value in predicting challenge outcome

International Consensus Guidelines AAAAI. A Nowak- Węgrzyn, et al (JACI 2017)

# **FPIES:** Foods

• On 462 children (1031 episodes) Most common foods were



Grain=rice oat, WHEAT very rare Meat=chicken, turkey Vegetables= sweet potato, peas, squash Fruit= Banana, apple

Ruffner et al JACI in practice 2014

# Foods That Trigger FPIES (Mount Sinai Data)





FIG 1. FPIES food triggers.

Caubet, et al. JACI 2014; 134:382-9


# **FPIES:** Foods

 On 462 children (1031 episodes) Most children were allergic to only 1-2 foods




Ruffner et al JACI in practice 2014

## T cell response to specific antigens in FPIES




Goswami et al JACI 2017

# T cell response to specific antigens in FPIES



Goswami et al JACI 2017

### **Innate immunity activation in FPIES**




#### T cells

-milk, soy, or rice-responsive T cells, and TNF- $\alpha$ -producing CD1541 T cells, were significantly lower in those with outgrown FPIES compared with those with active FPIES. However, levels were within the normal range and were inconsistent with a role in the pathophysiology of FPIES.

-pan–T-cell activation and redistribution from the circulation after a positive food challenge but not in those who had outgrown their FPIES **Innate immune system** 

-monocytes, neutrophils, natural killer cells, and eosinophils activated after food challenge only in children with active FPIES Goswami et al JACI 2017

#### What are the mechanism that cause FPIES




Berin C, JACI 2016.

#### Can FPIES become IgE mediated allergy?

160 children retrospectively studied

- 39% had IgE sensitization to another food.
- 24% subjects had positive specific IgE levels to the food inducing FPIES.
- Among children with specific IgE to cow's milk,41%changed from a milk FPIES to an IgE-mediated phenotype over time.
- none of the subjects with milk specific IgE became tolerant to milk during the study

#### Caubet et al JACI 2014



Modified from

http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/A/AntigenPresentati

on.html

#### Conclusions

- Non-IgE mediated allergies continue to provide unique challenges
- Lack of clear in vitro specific diagnostic test
- Difficulties in the diagnosis of Food allergy that rely heavily on Oral food challenges and EGD make these emerging diseases
- Ongoing studies maybe able to answer some of the questions

# Thanks

- ILSI Health & Environmental Sciences Institute (HESI)
- Protein Allergenicity Technical Committee (PATC) for invitation
- All the families and patients that participate to the study
- APFED/AAAAI
- FARE



## IgE mediated Wheat allergy


Table	Т	Allergens	in	wheat	flour
I avie		Allel gens		WITCal	noui

Allergen name	Allergen abbreviation	Molecular weight (kDa)	Reference
α-purothionin	Tri a 37	37	32-34
α-amylase/trypsin	Tri a 28 and	12-16	5,29
inhibitor	Tri a 29.01		
Peroxidase	Tri a Bd36 kd	36	37,38
Thioredoxin	Tri a 25	25	39-41
Lipid protein transfer	Tri a 14	14	29,35,36,128
Serine proteinase inhibitor	Tri a 29	9.9	42,43
Thaumatin-like protein (TLP)		21–26	44
Gliadin	ω-5-gliadin	65	30,31,45
Thiol reductase	Tri a 27	27	128,129
I-cys-peroxiredoxin	Tri a 32		128,130
Serine protease like inhibitor	Tri a 39		128,130

Wheat is a cereal grain composed of 4 fractions of proteins (ie,albumins, globulins, and "gluten" [gliadins and glutenins]), any of which might elicit an IgE-mediated allergic response. 16% of IgE mediated allergic patients to wheat react to Rye, up to 16-55% to barely, they usually tolerate oat

#### Humoral and cellular responses to casein in patients with food protein-induced enterocolitis to cow's milk

Jean Christoph Caubet, MD,<sup>a,b</sup> Ramon Bencharitiwong, PhD,<sup>b</sup> Andrew Ross, BA,<sup>b</sup> Hugh A. Sampson, MD,<sup>b</sup> M. Cecilia Berin, PhD,<sup>b</sup> and Anna Nowak-Węgrzyn, MD<sup>b</sup> *Geneva, Switzerland, and New York, NY* 



#### **JACI 2016**


# Humoral and cellular responses to casein in patients with food protein-induced enterocolitis to cow's milk

TABLE I. Summary of pathologic findings in patients with FPIES compared with control subjects

	Positive findings	Negative findings
Humoral responses	Lower levels of milk-specific IgG and IgG <sub>4</sub> in patients with CM-FPIES compared with those in patients tolerating CM (active vs resolved)	No difference in levels of specific and total IgM
	Trend toward lower ratios of casein-specific IgG4/total IgG in patients with active CM-FPIES and patients with resolved CM-FPIES compared with those in patients with CM-tolerant FPIES	No difference in levels of specific IgD to case in, $\alpha$ -lactalbumin, and $\beta$ -lactoglobulin
	Lower casein-specific IgM/total IgM ratio in patients with active CM-FPIES compared with that in patients tolerating CM	No difference in amounts of total $\kappa$ Ig-fLC, $\lambda$ Ig-fLC, CM-specific fLC, or $\lambda$ Ig-fLC/ $\kappa$ Ig-fLC ratio
	Significantly lower milk-specific λ Ig-fLC/κ Ig-fLC ratio in patients with active CM-FPIES compared with that in patients tolerating CM	
T-cell and cytokine responses	Significantly lower secretion of IL-10 in patients with CM-FPIES compared with that in patients with IgE-CMA	Proliferating casein-specific CD4 <sup>+</sup> T-cell frequency in patients with CM-FPIES similar to patients with IgE-CMA and control subjects
	Significantly higher IL-9-induced secretion in patients with CM-FPIES compared with that in patients with IgE-CMA	No difference found in $T_H^2$ cytokine secretion, as well as IFN- $\gamma$ and TNF- $\alpha$ secretion
Serum cytokines	<ul> <li>At baseline:</li> <li>1. Higher median concentration of IL-10 in patients with a negative OFC result compared with those with a positive OFC result</li> <li>2. Higher median IP-10 concentration in patients with a positive OFC result</li> </ul>	No change in the secretion of MCP-1, MIP-1 $\alpha$ , and MIP-1 $\beta$ after a positive OFC result
	Significant increase in IL-10 and IL-8 secretion after a positive OFC result	
Tryptase level before and after an OFC	Baseline serum tryptase levels significantly higher in patients with FPIES with a positive OFC result compared with levels in those with a negative OFC result	Serum tryptase levels not significantly different after a positive OFC result in patients with FPIES

MCP-1, Monocyte chemoattractant protein 1; MIP, macrophage inflammatory protein.

#### **Model of Milk induced inflammation in EoE**



Berin CM et al JACI 2008